🔍

Beta Drugs Limited (BETA)

₹1,783.00 +1.87% last close, 16 Oct

📊 NSE: BETA 🏢 Pharmaceuticals - Indian - Bulk Drugs 📢 Latest filing: 06 Oct 2026 📝 Analysis written: 13 Dec 2025

Q2 FY27 results

📅 Next results: 22 Oct 2026 (board meeting)

Beta Drugs Limited's board meets on 22 Oct 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Beta Drugs' revenue was ₹126 Cr (+25.5% year on year, +33.6% on the previous quarter), and net profit ₹15.8 Cr (+31.7% year on year); the operating margin was 21.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹126	+25.5%	+33.6%
Operating profit	₹27.4	+36.8%	+54.8%
Net profit	₹15.8	+31.7%	+74.6%
EPS (₹)	14.78	+27.5%	+65.5%
Operating margin	21.8%	—	—

Full quarterly financials → Results calendar →

BETA delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 44.73% of the BETA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 51.88%. That is close to its usual level.

44.73%Delivery, 16 Oct

51.88%Own 20-session average

0.8×Volume vs its average

₹1,783.00NSE close · +1.87%

Delivery in the last 5 sessions: 53.0% · 54.8% · 42.8% · 28.1% · 44.7%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Beta Drugs Receives Reg 74(5) Demat Confirmation for Quarter Ended Sep 30, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 06 Oct 2026, 10:25 AM

Beta Drugs Limited submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate issued by Registrar and Share Transfer Agent MUFG Intime India confirms that all dematerialisation requests received during the period were processed and confirmed within prescribed timelines. Additionally, corresponding physical share certificates were mutilated and cancelled. This is a routine quarterly compliance update with no material financial impact.

Compliance certificate received under Regulation 74(5) of SEBI Regulations, 2018
Covers the quarter ended 30th September 2026
Issued by RTA MUFG Intime India Private Limited on 03-10-2026
Confirms mutilation and cancellation of physical certificates upon dematerialisation

💡 No action needed by investors as this is a standard quarterly administrative filing. Watch for upcoming Q2 FY27 earnings announcements.

Beta Drugs Receives Azerbaijan Approvals for Oncology Portfolio; 30 Total Filings Planned

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 22 Sep 2026, 09:00 AM

Beta Drugs has received regulatory approvals in Azerbaijan for its oncology portfolio across liquid and lyophilised injectables, tablets, capsules, and oral suspensions. The company has already filed 15 oncology dossiers in Azerbaijan and plans to file another 15 within the next month, taking total filings to 30. Commercialisation and initial oncology revenue from the market are targeted within the current financial year. With TTM revenue at Rs 513 Cr, this move supports the company's broader strategy to expand international oncology exports into emerging markets.

Received oncology approvals across 4 dosage forms including liquid and lyophilised injectables, tablets, capsules, and oral suspensions
Already filed 15 oncology product dossiers for registration in Azerbaijan
Another 15 oncology products expected to be ready for filing within the next month
Commercialisation and initial business targeted during the current financial year

💡 Track the commercial launch timeline in upcoming quarterly updates and look for initial revenue contribution from Azerbaijan starting in H2 FY27.

Beta Drugs to Participate in Valorem CXO Meet on Sept 17; Targets ~25% Revenue CAGR to FY30

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Sep 2026, 03:15 PM

Beta Drugs announced its participation in a virtual group investor meet organized by Valorem Advisors on September 17, 2026. The company outlined its profile and targets under Vision 2030, targeting a ~25% revenue CAGR through FY30 after delivering a 5-year revenue CAGR of 27% and EBITDA CAGR of 25%. Beta Drugs operates 3 WHO-GMP certified facilities, reaches 85%+ of Indian corporate and government hospitals, and has 280+ dossier registrations across 46+ countries with ~300 additional filings pending.

Virtual group investor meeting scheduled for September 17, 2026, at 4:00 PM IST with Valorem Advisors
Company targeting ~25% revenue CAGR through FY30 under Vision 2030
Portfolio features 180+ oncology-focused SKUs reaching 85%+ of Indian corporate and government hospitals
Presence across 46+ countries backed by 280+ dossier registrations and ~300 registrations filed
Operates 3 WHO-GMP facilities, with 65%+ of internal APIs utilized for in-house formulation backward integration

💡 Track subsequent post-meet investor presentations or transcript disclosures for any updates on capital deployment or regulatory approvals in export markets like Mexico and South Africa.

Beta Drugs Issues Notice for 21st AGM Scheduled on September 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Sep 2026, 04:16 PM

Beta Drugs Limited has issued the notice for its 21st Annual General Meeting scheduled for September 30, 2026. Ordinary and special business items include the adoption of FY26 financial statements, reappointment of statutory auditors at Rs 4,20,000 per annum, and approval of cost auditor remuneration of Rs 1,25,000. Additionally, shareholders will vote on the reappointment and remuneration of Mr. Ashutosh Shukla as Whole-time Director for a 5-year term starting January 20, 2027, at Rs 3,94,419 per month. The cut-off date for remote e-voting is set for September 23, 2026.

21st Annual General Meeting scheduled for September 30, 2026
Cut-off date for remote e-voting fixed as September 23, 2026
Statutory auditor Khurana Sharma & Co. proposed for reappointment at Rs 4,20,000 p.a.
Proposed reappointment of Whole-time Director Ashutosh Shukla for 5 years at Rs 3,94,419 per month

💡 Eligible shareholders holding shares as of September 23, 2026, can cast their votes electronically between September 26 and September 29, 2026. Monitor the AGM voting outcome on September 30, 2026.

Beta Drugs Sets Book Closure from Sept 24 to Sept 30, 2026 for 21st AGM

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 06:09 PM

Beta Drugs Limited has announced the closure of its Register of Members and Share Transfer Books from September 24, 2026, to September 30, 2026 (both days inclusive). This closure is for the purpose of convening the company's 21st Annual General Meeting (AGM) on September 30, 2026. The meeting will take place at 10:30 a.m. at the company's registered office in Baddi, Himachal Pradesh.

21st Annual General Meeting scheduled for September 30, 2026, at 10:30 AM
Book closure period begins on September 24, 2026 (Thursday)
Book closure period concludes on September 30, 2026 (Wednesday)
Meeting to be held at the registered office in Baddi, Distt Solan, H.P.

💡 Track the full AGM notice and annual report for management commentary on export market filings and new NDDS launches.

Beta Drugs Schedules 21st AGM for September 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 06:04 PM

Beta Drugs Limited has announced that its 21st Annual General Meeting (AGM) will be convened on Wednesday, September 30, 2026, at 10:30 AM. The meeting will take place at the company's registered office located in Baddi, Solan, Himachal Pradesh. The full Notice and the Annual Report for FY2025-26 will be submitted to the stock exchange prior to dispatch to shareholders.

21st Annual General Meeting scheduled for September 30, 2026, at 10:30 AM
Physical venue set at the registered office in Baddi, Solan (H.P.)
Notice of AGM and FY26 Annual Report to be dispatched and filed with the exchange shortly

💡 Investors should track the upcoming dispatch of the FY26 Annual Report for updates on plant repurposing and export dossier filing milestones.

Beta Drugs Schedules 21st AGM on Sept 30, 2026; Reappoints WTD Ashutosh Shukla for 5 Years

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 03 Sep 2026, 05:56 PM

Beta Drugs Limited announced outcomes from its Board meeting held on September 3, 2026. The Board approved the draft notice for the 21st Annual General Meeting (AGM) scheduled for September 30, 2026, with share transfer books closed from September 24 to September 30, 2026. Additionally, the Board approved the re-appointment of Mr. Ashutosh Shukla as Whole-Time Director for a 5-year term from January 20, 2027, to January 19, 2032, subject to shareholder approval. The Board also re-appointed M/s Khurana Sharma and Co. as statutory auditors for a 2-year term starting FY27, along with appointments of cost and internal auditors.

21st Annual General Meeting scheduled for September 30, 2026, at 10:30 A.M.
Book closure fixed from September 24, 2026, to September 30, 2026 (both days inclusive)
Whole-Time Director Mr. Ashutosh Shukla re-appointed for a 5-year term (Jan 20, 2027 – Jan 19, 2032)
Statutory auditor M/s Khurana Sharma and Co. re-appointed for a period of 2 years (FY27 to FY28)
Charu Jindal & Co. and V.K. Srivastva & Associates appointed as Cost and Internal Auditors for FY27

💡 Track the upcoming AGM voting results on September 30, 2026, particularly resolutions regarding director remuneration revisions and auditor re-appointments.

Beta Drugs Allots 35,383 Bonus Equity Shares on CCD Conversion

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Aug 2026, 12:07 PM

Beta Drugs Limited's Board of Directors approved the allotment of 35,383 bonus equity shares of face value INR 10 each during its meeting on August 18, 2026. The allotment was executed in favour of Compulsorily Convertible Debenture (CCD) holders pursuant to conversion terms. Given the company's current market capitalisation of ₹1,722 Cr, this allotment entails negligible equity dilution.

Allotment of 35,383 Bonus Equity Shares approved by the Board.
Face value of newly allotted equity shares is INR 10 each.
Allotment made to holders of Compulsorily Convertible Debentures (CCDs) on conversion.
Board meeting concluded at 11:56 a.m. on August 18, 2026.

💡 Monitor subsequent filings for updated total paid-up share capital and listing/trading permissions for the new shares.

Beta Drugs Reports Q1-FY27 Revenue of ₹125.5 Cr and 21.8% EBITDA Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 27 Jul 2026, 09:24 PM

Beta Drugs Limited (BETA) demonstrated strong operational momentum in Q1-FY27, reporting revenue of ₹125.5 Cr, which represents approximately 26% of its TTM revenue in a single quarter. EBITDA margins improved to 21.83% in Q1-FY27 from 19.67% in FY26, driven by a high-margin oncology portfolio and new product launches. The company has strategically diversified into the IVF segment through the 66.09% acquisition of Nivian Life Sciences in April 2026. With a massive pipeline of 623 dossier registrations globally, the company is positioning itself for significant export-led growth.

Q1-FY27 revenue reached ₹125.5 Cr with an improved EBITDA margin of 21.83%
Acquired 66.09% stake in Nivian Life Sciences in April 2026 to enter the IVF therapy segment
Dossier registration pipeline stands at 623 units across LATAM, APAC, MENA, and CIS markets
New products contributed 25% to the total revenue in FY26, highlighting R&D efficiency
Debt-to-Equity ratio improved to 0.60x in FY26 from 0.70x in FY25

💡 Investors should monitor the revenue contribution from the newly acquired IVF business (Nivian) and the conversion rate of the 623-dossier pipeline into active export sales in regulated markets.

Beta Drugs submits revised Q1 FY27 results to include missing UDIN; Revenue at ₹127.13 Cr

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 23 Jul 2026, 05:54 PM

Beta Drugs Limited has submitted revised Standalone and Consolidated Limited Review Reports for the quarter ended June 30, 2026, following a clarification request from the NSE. The revision was necessary because the initial filing on July 20, 2026, inadvertently omitted the mandatory Unique Document Identification Number (UDIN). The underlying financial data remains consistent, showing consolidated total revenue of ₹127.13 Cr for Q1 FY27, which represents approximately 26.4% of the company's TTM revenue of ₹481 Cr. Consolidated net profit for the quarter was reported at ₹16.49 Cr.

Consolidated Total Revenue for Q1 FY27 reached ₹127.13 Cr compared to ₹96.46 Cr in the preceding quarter.
Consolidated Net Profit for the quarter ended June 30, 2026, stood at ₹16.49 Cr.
Standalone Revenue from Operations for the quarter was ₹55.83 Cr.
The revision specifically addresses the omission of the UDIN in the reports submitted on July 20, 2026.
Consolidated EPS for the quarter is reported at ₹14.78.

💡 Investors should treat this as a routine administrative correction. No changes to the financial performance figures were noted; focus should remain on the company's expansion into regulated markets like Mexico and South Africa.

Rs 117 Cr Preferential Issue: Beta Drugs Reports Zero Deviation in Fund Utilization for Q1 FY27

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 20 Jul 2026, 03:08 PM

Beta Drugs has confirmed zero deviation in the utilization of Rs 117.01 crore raised through a preferential issue in November 2024. As of June 30, 2026, the company has utilized Rs 47.87 crore, representing approximately 41% of the total proceeds. Significant spending has been directed toward capital investments (Rs 19.95 crore) and general corporate purposes (Rs 13.85 crore). However, utilization for R&D and geographical expansion remains low, with Rs 14.05 crore and Rs 10 crore still unspent in those respective categories.

Total funds raised via preferential issue on November 25, 2024, amounted to Rs 117.01 crore.
Cumulative funds utilized as of June 30, 2026, stand at Rs 47.87 crore.
Manufacturing capex (new setup) has seen utilization of Rs 9.52 crore against an allocation of Rs 44 crore.
Capital investment and acquisitions are nearly fully funded with Rs 19.95 crore utilized out of Rs 20 crore.
R&D facility setup shows slow progress with only Rs 0.95 crore utilized out of a Rs 15 crore budget.

💡 Investors should monitor the execution timeline for the remaining Rs 34.48 crore manufacturing capex and the R&D facility, as these are critical for the company's strategy to enter regulated markets.

40.9% PAT Growth in Q1FY27; Beta Drugs Reports Rs 125.55 Cr Sales and Margin Expansion

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 20 Jul 2026, 09:00 AM

Beta Drugs Limited reported a strong Q1FY27 with consolidated sales growing 25.3% YoY to Rs 125.55 Cr. Net profit surged 40.92% to Rs 16.5 Cr, significantly aided by a 64% reduction in interest costs following the conversion of CCDs in May 2026. Operating performance was robust with gross margins expanding to 56.6% (vs 50.4% YoY) driven by a shift toward high-margin branded oncology products, which grew 47% YoY. The company maintained its FY27 revenue growth guidance of 20-25%.

Consolidated total sales reached Rs 125.55 Cr, a 25.3% increase from Rs 100.2 Cr in Q1FY26.
Net Profit grew 40.92% YoY to Rs 16.5 Cr, representing ~32% of the total TTM PAT.
Branded Oncology segment delivered 47% YoY growth, recording sales of Rs 33.0 Cr.
Interest costs decreased to Rs 0.75 Cr from Rs 2.1 Cr YoY due to CCD conversion.
Consolidated EBITDA (excluding other income) grew by 38.9% YoY to Rs 27.37 Cr.

💡 Watch for the execution of the 'Vision 2030' strategy, specifically the ramp-up in export markets like Mexico and South Africa and the launch of new NDDS products in FY27.

Beta Drugs Limited: Routine Compliance Certificate for Dematerialization (Q1 FY27)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jul 2026, 10:43 AM

Beta Drugs Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended June 30, 2026. The Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited, confirmed that securities received for dematerialization were processed and listed on the stock exchanges. This is a standard procedural filing confirming that physical share certificates were cancelled and the register of members was updated within prescribed timelines. The filing has no impact on the company's financial health or business operations.

Covers the quarter ended 30th June 2026 for dematerialization activities.
Confirmation provided by MUFG Intime India Private Limited (formerly Link Intime India).
Certificates received were mutilated and cancelled after due verification by the depository participant.
Name of depositories substituted in the register of members as the registered owner within prescribed timelines.

💡 No action is required as this is a routine administrative filing. Investors should monitor the company's progress on its stated goal of filing 150+ dossiers in regulated markets over the next two years.

Beta Drugs Limited: Trading Window Closure from July 1, 2026, for Q1 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jun 2026, 12:58 PM

Beta Drugs Limited has announced the closure of its trading window for all designated persons starting July 1, 2026. This is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of financial results for the quarter ending June 30, 2026. The window will remain closed until 48 hours after the un-audited financial results are declared. This filing is administrative and does not reflect any change in the company's business operations or financial health.

Trading window closure effective from July 1, 2026.
Closure pertains to the un-audited financial results for the quarter ended June 30, 2026.
Window to reopen 48 hours after the official declaration of results.
Restriction applies to Directors, Officers, Designated Employees, and their immediate relatives.

💡 No action is required; investors should wait for the announcement of the board meeting date to review the company's Q1 FY27 financial performance.

Beta Drugs Clarifies No Undisclosed Information Behind Recent Price and Volume Movement

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 15 Jun 2026, 04:41 PM

Beta Drugs Limited has responded to a clarification request from the National Stock Exchange (NSE) regarding recent significant movements in its share price and trading volume. The company officially stated that there is no undisclosed price-sensitive information or material event that could be influencing the stock's behavior. Management characterized the recent activity as purely market-driven and outside of the company's control. The company reaffirmed its commitment to maintaining transparency and complying with SEBI (LODR) Regulations, 2015.

Response to NSE surveillance letter Ref. No. NSE/CM/Surveillance/17088 dated June 12, 2026.
Company confirms no pending material announcements or undisclosed price-sensitive information (UPSI).
Management attributes recent price and volume fluctuations entirely to market forces.
Reiteration of ongoing compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should remain cautious as the company has confirmed no fundamental news is driving the recent volume spurt. Focus on actual financial performance rather than speculative price movements.

View All BETA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 13% YoY to INR 203.6 Cr in H1 FY26. Segment growth: Domestic Own Brands grew 21% YoY (INR 69.4 Cr), CDMO grew 8% YoY (INR 79 Cr), International/Exports grew 10% YoY (INR 43.2 Cr), and API external sales grew 14% YoY (INR 12.25 Cr).

Geographic Revenue Split

Domestic sales (including Branded and CDMO) contribute approximately 73% of total revenue, while International/Export markets contribute 21%. The remaining 6% is derived from API sales.

Profitability Margins

Gross margins decreased by 1.5% to 51.35% in H1 FY26 due to product mix shifts. Operating margins are projected to remain between 20-22% through FY26. Branded business yields high EBITDA margins of 35-36%, while CDMO margins are lower at 16-17%.

EBITDA Margin

EBITDA margin improved to 23.08% in H1 FY26 from 22.36% in H1 FY25, a YoY increase of 72 bps. Excluding the newly break-even Derma division, core EBITDA margins stand higher at 24.12%.

Capital Expenditure

Net fixed assets increased from INR 88.93 Cr in FY25 to INR 111.52 Cr in H1 FY26, reflecting ongoing investments in machinery at the Adley plant and regulatory upgrades at the Beta plant.

Credit Rating & Borrowing

CRISIL BBB+/Stable. The company maintains low reliance on external debt with a gearing ratio of 0.07x as of March 2024. Interest coverage is robust at 11.26x in H1 FY26.

⚙️ Operational Drivers

Raw Materials

Oncology APIs and Platin group compounds. Platin group products represent a segment where margins are significantly lower (10-15% GC) compared to innovative products (50-70% GC).

Capacity Expansion

The company has added significant machinery and capacity at the Adley Formulation plant to handle 100% of domestic branded and CDMO production. The Beta standalone plant is being repurposed exclusively for regulated export markets.

Raw Material Costs

Raw material costs are subject to price volatility, particularly in the Platin group. Management utilizes a pass-through pricing strategy for own-branded products to mitigate margin erosion from input cost spikes.

Manufacturing Efficiency

RoCE was healthy at 37.2% in FY22 and is estimated to remain around 37% in FY24, driven by economies of scale and integrated in-house operations.

Logistics & Distribution

Distribution is supported by a strong sales network and diversified clientele including large government and private hospitals.

📈 Strategic Growth

Expected Growth Rate

20-25%

Growth Strategy

Shifting the Beta standalone plant to serve regulated markets (Mexico, South Africa, Vietnam) with 11 identified high-margin products. Doubling the regulatory team to file 150+ dossiers over the next two years and launching two new NDDS (New Drug Delivery Systems) products.

Products & Services

Oncology products (anti-cancer tablets), Dermatology products, and Oncology APIs.

Brand Portfolio

Not disclosed in available documents, though 6 brands are expected to reach INR 5 Cr in annual sales each.

New Products/Services

Launch of Methotrexate and two NDDS molecules expected to drive growth in H2 FY26 and beyond.

Market Expansion

Targeting regulated markets with 16 dossiers filed in Mexico, 4 in South Africa, and multiple filings in Algeria and Vietnam.

Strategic Alliances

Maintains CDMO relationships with major pharmaceutical companies; specific partner names not disclosed.

🌍 External Factors

Industry Trends

The oncology market is shifting toward regulated market compliance and complex delivery systems. Beta is positioning itself by upgrading plants for international audits (Mexico/Colombia) and developing NDDS molecules.

Competitive Landscape

Faces intense competition in the CDMO and branded generics space from both domestic and international pharmaceutical players.

Competitive Moat

Moat is built on specialized oncology manufacturing and backward integration into APIs, which is sustainable due to high entry barriers in cytotoxic (anti-cancer) drug production.

Macro Economic Sensitivity

Sensitive to healthcare spending and government tender cycles, particularly in the export segment which is largely tender-driven.

Consumer Behavior

Increasing prescriber base (up 8% in H1 FY26) indicates growing doctor acceptance of Beta's oncology brands.

Geopolitical Risks

Trade barriers or regulatory hurdles in target export geographies like Colombia and the Philippines could impact the planned 150+ dossier filings.

⚖️ Regulatory & Governance

Industry Regulations

Subject to stringent WHO-GMP and international regulatory audits (COFEPRIS Mexico, INVIMA Colombia). Successful completion of audits in H1 FY26 with no critical observations.